Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients

References

• Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of health and human services; 2021 [ cited 2021 Jun]. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf
   Google Scholar
• Thailand national guidelines on HIV/AIDS treatment and prevention bureau of AIDS, TB and STIs department of disease control, ministry of public health. 2017 [ cited 2019 Dec]. Available from: http://www.thaiaidssociety.org/images/PDF/hiv_thai_guideline_2560.pdf
   Google Scholar
• Croom KF, Dhillon S, and Keam SJ., et al. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs. 2009 May 29;69(8):1107–1140.
   Google Scholar
• Le TC, Barrail A, Goujard C, et al. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005;44(10):1035–1050.
   Google Scholar
• Griffin L, Annaert P, Brouwer KL., et al. Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J Pharm Sci. 2011 Sep;100(9):3636–3654.
   Google Scholar
• Larson KB, Wang K, Delille C, et al. Pharmacokinetic enhancers in HIV therapeutics. Clin Pharmacokinet. 2014 Oct;53(10):865–872.
   Google Scholar
• Winston A, Bloch M, Carr A, et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother. 2005 Aug;56(2):380–387.
   Google Scholar
• Colombo S, Buclin T, Cavassini M, et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006 Nov;50(11):3801–3808.
   Google Scholar
• Lamba J, Hebert JM, Schuetz EG, et al. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics. 2012 Jul;22(7):555–558.
   Google Scholar
• Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2012;64:256–269.
   Google Scholar
• Kile DA, MaWhinney S, Aquilante CL, et al. A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses. 2012 Oct;28(10):1227–1234.
   Google Scholar
• Savic RM, Barrail-Tran A, and Duval X, et al. Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. Clin Pharmacol Ther. 2012 Nov;92(5):575–583.
   Google Scholar
• Anderson PL, Aquilante CL, and Gardner EM, et al. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother. 2009 Nov;64(5):1071–1079.
   Google Scholar
• Singkham N, Avihingsanon A, Thammajaruk N, et al. Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients. Pharmacogenomics. 2019 May;20(7):517–527.
   Google Scholar
• Wolking S, Schaeffeler E, Lerche H, et al. Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet. 2015 Jul;54(7):709–735.
   Google Scholar
• Alam C, Whyte-Allman SK, Omeragic A, et al. Role and modulation of drug transporters in HIV-1 therapy. Adv Drug Deliv Rev. 2016 Aug 01;103:121–143.
   Google Scholar
• Rodriguez NS, Barreiro P, Rendon A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C–>T polymorphism at the multidrug resistance gene 1. Clin Infect Dis. 2006 Jan 15;42(2):291–295.
   Google Scholar
• Rodriguez NS, Martin-Carbonero L, and Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. Aids. 2007 Jan 02;21(1):41–46.
   Google Scholar
• D’Avolio A, Carcieri C, Cusato J, et al. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J Antimicrob Chemother. 2014 Nov;69(11):3061–3066.
   Google Scholar
• Avihingsanon A, Tongkobpetch S, Kerr SJ, et al. Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia. J Acquir Immune Defic Syndr. 2015 May 1;69(1):e36–37.
   Google Scholar
• Rakhmanina NY, Neely MN, Van Schaik RH, et al. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther Drug Monit. 2011 Aug;33(4):417–424.
   Google Scholar
• Ihunnah CA, Jiang M, and Xie W., et al. Nuclear receptor PXR, transcriptional circuits and metabolic relevance. Biochim Biophys Acta. 2011 Aug;1812(8):956–963.
   Google Scholar
• Siccardi M, D’Avolio A, Baietto L, et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→ T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis. 2008;47(9):1222–1225.
   Google Scholar
• Schipani A, Siccardi M, D’Avolio A, et al. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother. 2010 Dec;54(12):5242–5250.
   Google Scholar
• Winston A, Jose S, Gibbons S, et al. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother. 2013 Jun;68(6):1354–1359.
   Google Scholar
• Punyawudho B, Thammajaruk N, and Ruxrungtham K, et al. Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients. Int J Antimicrob Agents. 2017 Mar;49(3):327–332.
   Google Scholar
• Amadasi S, Odolini S, Foca E, et al. Evaluation of boosted and unboosted atazanavir plasma concentration in HIV infected patients. Curr HIV Res. 2013 Dec;11(8):642–646.
   Google Scholar
• Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004 Jun;48(6):2091–2096.
   Google Scholar
• Dailly E, Tribut O, Tattevin P, et al. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. Eur J Clin Pharmacol. 2006 Jul;62(7):523–526.
   Google Scholar
• Stohr W, Back D, Dunn D, et al. Factors influencing lopinavir and atazanavir plasma concentration. J Antimicrob Chemother. 2010 Jan;65(1):129–137.
   Google Scholar
• Venuto CS, Mollan K, Ma Q, et al. Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS clinical trials group study A5202. J Antimicrob Chemother. 2014 Dec;69(12):3300–3310.
   Google Scholar
• Goutelle S, Baudry T, Gagnieu MC, et al. Pharmacokinetic-pharmacodynamic modeling of unboosted atazanavir in a cohort of stable HIV-infected patients. Antimicrob Agents Chemother. 2013 Jan;57(1):517–523.
   Google Scholar
• Barco E, Nóvoa S. The pharmacogenetics of HIV treatment: a practical clinical approach. J Pharmacogenomics Pharmacoproteomics. 2013;4:116.
   Google Scholar
• Calcagno A, Cusato J, D’Avolio A, et al. Genetic polymorphisms affecting the pharmacokinetics of antiretroviral drugs. Clin Pharmacokinet. 2017 Apr;56(4):355–369.
   Google Scholar
• Avihingsanon A, van der Lugt J, Kerr SJ, et al. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin Pharmacol Ther. 2009 Apr;85(4):402–408.
   Google Scholar
• Avihingsanon A, Apornpong T, Kerr S, et al. Low-dose ritonavir-boosted atazanavir (200/100 mg) maintained a high virological efficacy up to 4 years in treatment-experienced HIV-1 infected adults: a prospective cohort study from Asia. J AIDS Clin Res. 2015;6(5). DOI:10.4172/2155-6113.1000460.
   Google Scholar
• Bunupuradah T, Kiertiburanakul S, and Avihingsanon A, et al. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial. Lancet HIV. 2016 Aug;3(8):e343–350.
   Google Scholar
• Burger D, Teulen M, Eerland J, et al. The international interlaboratory quality control program for measurement of antiretroviral drugs in plasma: a global proficiency testing program. Ther Drug Monit. 2011 Apr;33(2):239–243.
   Google Scholar
• QIAamp® DNA mini and blood mini handbook [internet]. QIAGEN; 2016 [ cited 2017 Nov]. Available from: file:///C:/Users/Administrator/Downloads/HB-0329-004-1102728-HB-QIAamp-DNA-Mini-Blood-Mini-0516-WW%20(1).pdf
   Google Scholar
• Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal. . 1999 Feb;14(5–6):143–149.
   Google Scholar
• Boekmann AJ, Sheiner LB, Beal SL., et al. NONMEM user’s guide, part V: introductory guide. San Francisco (CA): NONMEM Project Group: University of California; 1994.
   Google Scholar
• Keizer RJ, Karlsson MO, Hooker A., et al. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013 Jun;26(2):1–9.
   Google Scholar
• Jonsson EN, Karlsson MO. Xpose–an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999 Jan;58(1):51–64.
   Google Scholar
• Zhang L, Beal SL, Sheiner LB., et al. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):387–404.
   Google Scholar
• Ette EI, Williams PJ, Kim YH, et al. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003 Jun;43(6):610–623.
   Google Scholar
• Jadhav PR, Gobburu JV. A new equivalence based metric for predictive check to qualify mixed-effects models. AAPS J. 2005;7(3):E523–E531.
   Google Scholar
• Dickinson L, Boffito M, Back D, et al. Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. J Antimicrob Chemother. 2009 Jun;63(6):1233–1243.
   Google Scholar
• Solas C, Gagnieu MC, Ravaux I, et al. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients. Ther Drug Monit. 2008 Dec;30(6):670–673.
   Google Scholar
• Schipani A, Dickinson L, and Boffito M, et al. Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. J Acquir Immune Defic Syndr. 2013 Jan 01;62(1):60–66.
   Google Scholar
• Molto J, Estevez JA, Miranda C, et al. Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients. Br J Clin Pharmacol. 2016 Dec;82(6):1528–1538.
   Google Scholar
• Solas C, Simon N, Drogoul MP, et al. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br J Clin Pharmacol. 2007 Sep;64(3):353–362.
   Google Scholar
• Gandhi M, Aweeka F, Greenblatt RM, et al. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44(1):499–523.
   Google Scholar
• Ofotokun I, Chuck SK, Hitti JE., et al. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med. 2007 Jun;4(2):106–119.
   Google Scholar
• Zhang C, Denti P, Decloedt EH, et al. Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin. Br J Clin Pharmacol. 2013 Nov;76(5):741–751.
   Google Scholar
• Hsu A, Granneman GR, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 1997 May;41(5):898–905.
   Google Scholar
• Castillo-Mancilla JR, Aquilante CL, Wempe MF, et al. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS clinical trials group (ACTG) PEARLS study (NWCS 342). J Antimicrob Chemother. 2016 Jun;71(6):1609–1618.
   Google Scholar